Canadian Cancer Trials Group Bulletins

Trial Management Group


Trial Activations

CO.26 - A Phase II Randomized Study of Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care Alone in Patients with Advanced Colorectal Adenocarcinoma Refractory to Standard Therapies - was centrally activated on August 10, 2016.

The primary objective of this trial is to determine the effect on overall survival of the combination of durvalumab and tremelimumab and best supportive care versus best supportive care only in patients with refractory, advanced colorectal cancer.

Secondary objectives are to:
  • Determine the effect on progression-free survival of the combination of durvalumab and tremelimumab and best supportive care versus best supportive care only in patients with refractory, advanced colorectal cancer;
  • Assess the toxicity and safety of the combination of durvalumab and tremelimumab and best supportive care in patients with refractory, advanced colorectal cancer; and,
  • Determine the effect on objective response rate of the combination of durvalumab and tremelimumab and best supportive care.
Centres interested in participating in this trial should contact Nadine Magoski, Study Coordinator, at nmagoski@ctg.queensu.ca.

More information about this trial can be found using this link ... https://www.ctg.queensu.ca/trials/gastro-intestinal/co26.
____________________________________________

REC.3 (SWOG S1500) - A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib, Crizotinib, Savolitinib, and Sunitinib) in Metastatic Papillary Renal Carcinoma (PAPMET) - was centrally activated on July 27, 2016.

The primary objective of this trial is to to compare progression-free survival (PFS) in patients with metastatic papillary renal cell carcinoma (mPRCC) treated with sunitinib to PFS in patients with mPRCC treated with MET kinase inhibitors.

Secondary objectives are to:
  • Compare RECIST response rate (RR; defined as the combined rate of confirmed and unconfirmed PR and confirmed and unconfirmed CR) in patients with mPRCC treated with sunitinib to RR in patients treated with putative MET inhibitors;
  • Compare overall survival (OS) in patients with mPRCC treated with sunitinib to OS in patients with mPRCC treated with putative MET inhibitors; and,
  • Compare the safety profile of sunitinib and putative MET inhibitors in patients with mPRCC.
Centres interested in participating in this trial should contact Paul Stos, Study Coordinator, at pstos@ctg.queensu.ca.

More information about this trial can be found using this link ... https://www.ctg.queensu.ca/trials/genito-urinary/rec3.